These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2556232)

  • 21. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.
    D'Angelo A; Seveso MP; D'Angelo SV; Gilardoni F; Dettori AG; Bonini P
    Am J Clin Pathol; 1990 Sep; 94(3):297-306. PubMed ID: 2396604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of APTT factor sensitivity--the misguiding guideline.
    Lawrie AS; Kitchen S; Efthymiou M; Mackie IJ; Machin SJ
    Int J Lab Hematol; 2013 Dec; 35(6):652-7. PubMed ID: 23718922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variation among commercial activated partial thromboplastin time reagents in response to heparin.
    Shapiro GA; Huntzinger SW; Wilson JE
    Am J Clin Pathol; 1977 May; 67(5):477-80. PubMed ID: 857645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents.
    Ten Boekel E; Böck M; Vrielink GJ; Liem R; Hendriks H; de Kieviet W
    Thromb Res; 2007; 121(3):361-7. PubMed ID: 17568658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
    Kitchen S; Woolley A
    Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significantly different coagulation factor activities underlying the variability of 'normal' activated partial thromboplastin time.
    Park KJ; Kwon EH; Ma Y; Park IA; Kim SW; Kim SH; Kim HJ
    Blood Coagul Fibrinolysis; 2012 Jan; 23(1):35-8. PubMed ID: 22027757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A proposed model to monitor heparin therapy using the concentrated thrombin time which allows standardisation of reagents and improved estimation of heparin concentrations.
    Ray MJ; Perrin EJ; Smith IR; Hawson GA
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):515-21. PubMed ID: 8874861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent.
    Brancaccio V; Ames PR; Glynn J; Iannaccone L; Mackie IJ
    Blood Coagul Fibrinolysis; 1997 Apr; 8(3):155-60. PubMed ID: 9167015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated amidolytic method for evaluating the activated partial thromboplastin time compared with a conventional coagulation method.
    Tripodi A; Poggio M; Scapellato L; Mannucci PM
    Haemostasis; 1989; 19(4):205-12. PubMed ID: 2509308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of calcium ions on the activated partial thromboplastin time of heparinized plasma.
    Greenberg CS; Adams JP; Mullen PE; Koepke JA
    Am J Clin Pathol; 1986 Oct; 86(4):484-9. PubMed ID: 3766461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Lupus anticoagulant screening: comparison of 5 tests (author's transl)].
    Follea G; Ffrench P; Trzeciak MC; Dechavanne M
    Nouv Rev Fr Hematol (1978); 1981; 23(4):203-7. PubMed ID: 7312614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of factor VIII:C and factor IX activity in plasmas of haemophilic dogs on the activated partial thromboplastin time measured with two commercial reagents.
    Mischke R
    Haemophilia; 2000 May; 6(3):135-9. PubMed ID: 10792470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Easy Method to Eliminate the Effect of Lupus Anticoagulants in the Coagulation Factor Assay.
    Tang N; Yin S
    Clin Lab; 2016 Jul; 62(7):1363-1365. PubMed ID: 28164630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated partial thromboplastin time and minor coagulopathies.
    Hathaway WE; Assmus SL; Montgomery RR; Dubansky AS
    Am J Clin Pathol; 1979 Jan; 71(1):22-5. PubMed ID: 420168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARTIAL THROMBOPLASTIN TIME TEST WITH KAOLIN. NORMAL RANGE AND MODIFICATIONS FOR THE DIAGNOSIS OF HAEMOPHILIA AND CHRISTMAS DISEASE.
    MATCHETT MO; INGRAM GI
    J Clin Pathol; 1965 Jul; 18(4):465-71. PubMed ID: 14318702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid loss of factor XII and XI activity in ellagic acid-activated normal plasma: role of plasma inhibitors and implications for automated activated partial thromboplastin time recording.
    Joist JH; Cowan JF; Khan M
    J Lab Clin Med; 1977 Dec; 90(6):1054-65. PubMed ID: 303667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of the activated partial thromboplastin time for monitoring heparin therapy: problems and possible solutions.
    Poller L; Thomson JM; Taberner DA
    Ric Clin Lab; 1989; 19(4):363-70. PubMed ID: 2633304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The APTT monitoring of heparin--the ISTH/ICSH collaborative study.
    Van der Velde EA; Poller L
    Thromb Haemost; 1995 Jan; 73(1):73-81. PubMed ID: 7740500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The control of heparin therapy by the activated partial thromboplastin time: results of collaborative studies.
    Thomson JM
    Scand J Haematol Suppl; 1980; 37():73-83. PubMed ID: 6941440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.